Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.

Journal of psychiatric research - 1 Mar 2009

Shen Yu-Chih, Chen Shih-Fen, Chen Chia-Hsiang, Lin Chaucer C H, Chen Shaw-Ji, Chen Yu-Jung, Luu Sy-Ueng

Abstract excerpt

OBJECTIVES: Aripiprazole, a novel antipsychotic agent, acts as a partial agonist at dopamine D2 receptors (DRD2). We investigate whether its efficacy is predictable by DRD2/ANKK1 gene polymorphisms and clinical factors in Han Chinese hospitalized patients with acutely exacerbated schizophrenia. M...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Hospitalization
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Psychiatric Status Rating Scales

Share to Quinolones

Share to Receptors, Dopamine D2

Share to Schizophrenia

Share to Taiwan

Source

Identifiers

PMID: 18926547
DOI: 10.1016/j.jpsychires.2008.09.005

Genes

DRD2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18926547-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.PMID 18926547Read ↗

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.Semantic proximity Read ↗

Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.Semantic proximity Read ↗

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.Semantic proximity Read ↗

The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.Semantic proximity Read ↗

DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia.Semantic proximity Read ↗

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patientsSemantic proximity Read ↗

Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Semantic proximity Read ↗

Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphismsSemantic proximity Read ↗

No influence of DTNBP1 polymorphisms on the response to aripiprazole.Semantic proximity Read ↗

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Semantic proximity Read ↗

DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary studySemantic proximity Read ↗

DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.